

REFERENCES

References

- Addy, D., & Ritter, A. (2000). *Clinical Treatment Guidelines for Alcohol and Drug Clinicians. No 3: Relapse Prevention*. Victoria: Turning Point Alcohol and Drug Centre Inc.
- Alcohol & Other Drugs Unit of the Commonwealth Department of Health and Ageing. (2008). *Culturally and Linguistically Diverse (CALD) Groups*. Canberra: Commonwealth Department of Health and Ageing.
- Alcohol and Drug Dependence Act 1968 (Tas) (Austl)*.
- Amass, L., Bickel, W. K., Crean, J. P., Blake, J. & Higgins, S. T. (1998) Alternate-day Buprenorphine dosing is preferred to daily dosing by opioid-dependent humans, *Psychopharmacology*, 136, 217–225.
- American Psychiatric Association (2000) *Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition- TR)*. Washington DC: American Psychiatric Association.
- American Psychiatric Association (2006). Substance use disorders (2nd ed.). *In American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium*. http://www.psychiatryonline.com/PracGuide/pracGuideTopic_5.aspx
- Anthony, J.E. (1988), 'The response to overwhelming stress in children: some introductory comments', in Anthony J.E. (Ed.) *The Child in His Family*, John Wiley, New York.
- Assessing Fitness to Drive: 3rd Edition* (2006) Retrieved May 27, 2011, from <http://www.austroads.com.au/aftd>
- Austin, M.V. & Mitchell, P.B. (1998). Psychotropic medications in pregnant women: treatment dilemmas. *The Medical Journal of Australia*, 169, 428-431.
- Australian Bureau of Statistics (2008). *National Survey of Mental Health and Wellbeing: Summary of Results*. Canberra: ABS.
- Australian Bureau of Statistics, (2010). *National Health Survey: Summary of Results, 2007/08 (Reissue)*. Canberra: ABS.
- Australian Bureau of Statistics. (2001). *Census of Population and Housing: Selected Characteristics for Urban Centres and Localities, Tasmania*.
- Australian Institute of Health and Welfare (1999). *1998 National Drug Strategy Household Survey: First Results*. AIHW Cat. No. PHE 15, (Drug Statistics Series). Canberra: AIHW.

- Australian Institute of Health and Welfare (2002a). *2001 National Drug Strategy Household Survey: First Results*. AIHW Cat. No. PHE 35, (Drug Statistics Series). Canberra: AIHW.
- Australian Institute of Health and Welfare (2002b). *2001 National Drug Strategy Household Survey: State and Territory Supplement*. AIHW Cat. No. PHE 37, (Drug Statistics Series). Canberra: AIHW.
- Australian Institute of Health and Welfare (2005). *Alcohol and other drug treatment services in Tasmania: Findings from the National Minimum Data Set (NMDS) 2003-04*, Drug Statistics Series. Canberra: AIHW.
- Australian Institute of Health and Welfare (2005a). *2004 National Drug Strategy Household Survey: First Results*. AIHW Cat. No. PHE 57, Drug Statistics Series No. 13. Canberra: AIHW.
- Australian Institute of Health and Welfare (2005b). *2004 National Drug Strategy Household Survey: State and Territory Supplement*. AIHW Cat. No. PHE 66, Drug Statistics Series No. 16. Canberra: AIHW.
- Australian Institute of Health and Welfare (2006). *Alcohol and other drug treatment services in Tasmania: Findings from the National Minimum Data Set (NMDS) 2004-05*, Drug Statistics Series. Canberra: AIHW.
- Australian Institute of Health and Welfare (2007). *Alcohol and other drug treatment services in Tasmania: Findings from the National Minimum Data Set (NMDS) 2005-06*, Drug Statistics Series. Canberra: AIHW.
- Australian Institute of Health and Welfare (2008a). *2007 National Drug Strategy Household Survey: First Results*. AIHW Cat. No. PHE 98, Drug Statistics Series No. 20. Canberra: AIHW.
- Australian Institute of Health and Welfare (2008b). *2007 National Drug Strategy Household Survey: State and Territory Supplement*. AIHW Cat. No. PHE 102, Drug Statistics Series No. 21. Canberra: AIHW.
- Australian Institute of Health and Welfare (2008c). *Alcohol and other drug treatment services in Tasmania: Findings from the National Minimum Data Set (NMDS) 2006-07*, Drug Statistics Series. Canberra: AIHW. 206.
- Australian Institute of Health and Welfare (2009). *Alcohol and other drug treatment services in Tasmania: Findings from the National Minimum Data Set (NMDS) 2007-08*, Drug Statistics Series. Canberra: AIHW.
- Australian Institute of Health and Welfare (2010). *Alcohol and other drug treatment services in Australia 2008–09: report on the National Minimum Data Set*. Drug treatment series no. 10. Cat. no. HSE 92. Canberra: AIHW.

- Ayonrinde, O. & Bridge, D. (2000). The rediscovery of methadone for cancer pain management. *Medical Journal of Australia*, 173(10), 536-40.
- Barker, M.J., Jackson, M., Greenwood, K.M., Crowe, S. (2003). Cognitive Effects of Benzodiazepine Use: A Review. *Australian Psychologist*, 38; 202-213.
- Beck, A. T., Wright, F. W., Newman, C. F., & Liese, B. (1993). *Cognitive therapy of substance abuse*. New York: Guilford.
- Bell, J., Butler, B., Lawrance, A., Batey, R., & Salmelainen, P. (2009a). Comparing overdose mortality associated with methadone and buprenorphine treatment. *Drug and Alcohol Dependence*, 104(1-2), 73-77.
- Bell, J.,J., Trinh, L.,L., Butler, B.,B., Randall, D.,D., & Rubin, G.,G. (2009b). Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. *Addiction (Abingdon, England)*, 104(7), 1193-1200.
- Bernard J (1981). *The female world*. New York: Free Press.
- Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O. (1995). Buprenorphine treatment of refractory depression. *Journal of Clinical Psychopharmacology*, 15(1), 49-57.
- Caplehorn, J. (1998). Deaths in the first two weeks of maintenance treatment in NSW in 1994: Identifying cases of iatrogenic methadone toxicity. *Drug and Alcohol Review*, 17(1), 9-9.
- Cash, R. & Philactides, A. (2006). *Clinical Treatment Guidelines for Alcohol and Drug Clinicians. No. 14: Co-occurring acquired brain injury/cognitive impairment and alcohol and other drug use disorders*. Victoria: Turning Point Alcohol and Drug Centre.
- Chalmers, J., Ritter, A., Heffernan, M. & McDonnell, G. (2009). *Modelling pharmacotherapy maintenance in Australia: exploring affordability, accessibility and quality using system dynamics*. Australian National Council on Drugs Research Paper No. 19. ANCD: Canberra.
- Chen, Y., & Lader, M. (1990). Long-term benzodiazepine treatment: Is it ever justified? *Human Psychopharmacology: Clinical and Experimental*, 5(4), 301-312.
- Children, Young Persons and Their Families Act 1997 (Tas) (Austl)*.
- Chrisman, N.,J., & Zimmer, P. (2000). Cultural Competence in Primary Care. In P. V. Meredith and N. M. Horan (Eds.) *Adult Primary Care*.(Eds). Philadelphia: W.B. Saunders.
- Copeland, J., Hall, W., Didcott, P.; and Biggs, U. (1993). A comparison of a specialist women's alcohol and other drug treatment service with two traditional mixed sex services; client characteristics and treatment outcome. *Drug Alcohol Dependence*, 32,(1),81-92.

- Cowen, L., Deering, D., Crowe, M., Sellman, D., Futterman-Collier, A., Adamson, S. (2003). 'Alcohol and drug treatment for women: clinicians' beliefs and practices'. *International Journal of Mental Health Nursing*, 12: 48-55.
- De Boni, R., Bozzetti, M., Hilgert, J., Sousa, T., Von Diemen, L., Benzano, D. (2011). Factors associated with alcohol and drug use among traffic crash victims in southern Brazil. *Accident Analysis and Prevention*, 43(4), 1408-13.
- de Graaff, B. & Bruno. R. (2011) *Tasmanian Drug Trends 2010: Findings from the Illicit Drug Reporting System* National Drug and Alcohol Research Centre Australian Drug Trends Series No. 59, Sydney: University of New South Wales.
- Dean, A., Bell, J., Macdonald, C. & Mattick, R. (2004) Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. *European Psychiatry*. 19, 510-13.
- Debrato, Debra. & Hammer J, Hayes. (2002). Assessment and treatment of juvenile offenders. In D.H. Schetky & E.P. Benedek (Eds). *Principles and Practice of Child and Adolescent Forensic Psychiatry* (pp 267 – 278). Washington, DC: American Psychiatric Publishing.
- Degenhardt, L., Black, E., Breen, C., Bruno, R., Kinner, S., Roxburgh, A., Fry, C., Jenkinson, R., Ward, J., Fetherston, J., Weekley, J. & Fischer, J. (2006) Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. *Drug and Alcohol Review*. 25, 403-12.
- Department of Health and Ageing (2007). *National Pharmacotherapy Policy for People Dependent on Opioids*. National Drug Strategy. Canberra: Australian Government.
- Department of Health and Ageing, (1997). National Methadone Policy. Canberra: Australian Government.
- Department of Health and Ageing, (2001). National Buprenorphine Policy. Canberra: Australian Government.
- Department of Health and Ageing, National Clinical Guidelines and Procedures for the Use of Buprenorphine/Methadone in the Treatment of Opioid Dependence. Canberra: Australian Government.
- Department of Health and Ageing, Therapeutic Goods Association (2011) Prescribing medicines data base. Retrieved September 16, 2011, from <http://www.tga.gov.au/hp/medicines-pregnancy.htm>
- Department of Health and Human Services. (2008). Tasmanian Perinatal Database. Tasmania: Epidemiology Unit, Population Health. Hobart: Tasmanian Government
- Department of Health New South Wales (2008) *NSW Drug and Alcohol Withdrawal Clinical Practice Guidelines*. Mental Health and Drug & Alcohol Office: NSW: Department of Health.

- Department of Health, NSW (2006). Opioid Treatment Program: Clinical guidelines for methadone and buprenorphine treatment. Sydney: NSW Health.
- Department of Health, Western Australia Government and the Drug and Alcohol Office, (2006). Clinical policies and procedures for the use of methadone and buprenorphine in the treatment of opioid dependence. Perth: Western Australian Government.
- Department of Human Services, Victoria, Drugs Policy and Services Branch, (2006). Policy for Maintenance Pharmacotherapy for Opioid Dependence.
- Dey, P., Roaf, E., Collins, S., Shaw, H., Steele, R., & Donmall, M. (2002). Randomized controlled trial to assess the effectiveness of a primary health care liaison worker in promoting shared care for opiate users. *Journal of Public Health Medicine*, 24, 38.
- Drummer, O., Opeskin, K., Syrjanen, M & Cordner, S. (1992). Methadone toxicity causing death in ten subjects starting on a methadone maintenance program. *American Journal of Forensic Medical Pathology*. 13(4), 346-50.
- Drummond, C. & Perryman, K. (2007). *Psychosocial interventions in pharmacotherapy opioid dependence: a literature review*. World Health Organization: Geneva.
- Drummond, D.C., & Perryman, K. (2007). *Psychosocial interventions in pharmacotherapy for opioid dependence: a literature review*. Background document prepared for the third meeting of Technical Development Group (TDG) for the WHO “Guidelines for Psychosocially Assisted Pharmacotherapy of Opiate Dependence, 17-21 September Geneva, Switzerland.
- Dunlop, A., Panjari, M., O’Sullivan, H., Henschke, P., Love, V., Ritter, A. & Lintzeris, N. (2003). *Clinical Guidelines for the Use of Buprenorphine in Pregnancy*. Victoria: Turning Point Alcohol and Drug Centre.
- Eap, C., Deglon, J. & Boumann, P. (1999). Pharmacokinetics and pharmacogenetics of methadone: Clinical relevance. *Heroin Addiction and Related Clinical Problems: the official journal of EUROPAD, European Opiate Addiction Treatment Association* 1 (1): 19–34.
- Ebner, N., Rohrmeister, K., Winklbaur, B., Baewert, A., Jagsch, R., Peterzell, A., Thau, K. & Fischer, G. (2006). Management of neonatal abstinence syndrome in neonates born to opioid dependent women. *Drug and Alcohol Dependence*. 87(2-3), 131-38.
- Engel, G.L. (1977). The need for a new medical model: a challenge for biomedicine. *Science*, 196, 129-36.
- Enoch, M. (2011). The role of early life stress as a predictor for alcohol and drug dependence. *Psychopharmacology*. 214(1), 17-31.
- Family Violence Act 2004 (Tas) (Austl)*.
- Felice, A.M. & Koumitsidis, C. (2008). Shared care for the treatment of opioid dependence and the new General Medical Services contract. *Psychiatric Bulletin*, 32, 88-90.

- Fernandez-Serrano, M., Perez-Garcia, M. & Verdejo-Garcia (2011). What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance? *Neuroscience and Biobehavioural Reviews*, 35(3), 377-406
- Firearms Act 1996 (Tas) (Austl).*
- Fleming, P. & Lair, P. (2007). Sudden Infant Death Syndrome and Parental Smoking. *Early Human Development*, 83(11), 721-25.
- Ford, C., Barnard, J., Bury, J., Carnwath T., Gerada, C., Joyce, A., Keen, J., Lowe, C., Nelles, B., Roberts, K., Sander-Hess, C., Schofield P., Scott, J., Watson, R., & Wolff, K. (2005). *Guidance for the use of methadone for the treatment of opioid dependence in primary care. (1st ed.)*. England: RCGP Substance Misuse Unit, SMMGP, RCGP Sex, Drugs and HIV Task Group and the Alliance.
- Gibson, A. & Degenhardy, L. (2005) *Mortality related to Naltrexone in the treatment of opioid dependence; a comparative analysis*. Technical Report No. 229. Sydney: National Drug and Alcohol Research Centre.
- Gibson, A.E., Doran, C.M., Bell, J.R., Ryan, A., & Lintzeris, N. (2003). A comparison of buprenorphine treatment in clinical and primary settings: a randomized trial. *Medical Journal of Australia*, 179, 38.
- Gjerde, H., Normann, P. T., Christophersen, A. S., Samuelsen, S. O., & Mørland, J. (2011). Alcohol, psychoactive drugs and fatal road traffic accidents in Norway: A case-control study. *Accident Analysis and Prevention*, 43(3), 1197-203.
- Gjersing, L., Waal, H., Caplehorn, J., Gossop, M. & Clausen, T. (2010). Staff attitudes and the associations with treatment organisation, clinical practices and outcome in opioid maintenance treatment. *BMC Health Services Research*. 10 (194).
- Gowing, L., Farrell, M., Bornemann, R., Sullivan, L. & Ali, R. (2008). Substitution treatment of injecting opioid users for prevention of HIV infection. *Cochrane Database of Systematic Reviews*, Issue 2. Art. No.: CD004145. DOI: 10.1002/14651858.CD004145.pub3
- Gowing, L., Proudfoot, H., Henry-Edwards, S. & Teesson, M. (2001). *Evidence supporting treatment: the effectiveness of interventions for illicit drugs*. Canberra: Australian Council on Drugs:
- Graham, C., & Meechan, J. (2005). Dental management of patients taking methadone. *Dental Update*, 32(8), 477-8, 481-2, 485.
- Gray, A. (2007). *Systematic review of the safety of buprenorphine, methadone and naltrexone*. Geneva: World Health Organization.
- Greenfield, L. & Fountain, D. (2000). Influence of Time in Treatment and Follow-up Duration of Methadone Treatment Outcomes. *Journal of Psychopathology and Behavioural Assessment*, 22(4), 353-64.

- Greenwald, M., Johanson, C., Moody, D., Woods, J., Kilbourn, M., Koeppe, R., Schuster, C. & Zubieta, J. (2003). Effects of Buprenorphine Maintenance Dose on μ -Opioid Receptor Availability, Plasma Concentrations, and Antagonist Blockade in Heroin-Dependent Volunteers. *Neuropsychopharmacology*, 28, 2000–2009.
- Grella CE (2006). 'The Drug Abuse Treatment Outcomes Studies: outcomes with adolescent substance abusers.' In H. A. Liddle & C. L. Rowe (Eds.) *Adolescent Substance Abuse: Research and Clinical Advances*, (pp. 148-173). Cambridge: Cambridge University Press
- Grella, C.E., Hser, Y-I., Joshis, V., & Rounds-Bryant, J. (2001). Drug treatment outcomes for adolescents with comorbid mental and substance use disorders. *Journal of Nervous and Mental Disease*, 189, 384-92.
- Gruber, S. A., Tzilos, G. K., Silveri, M. M., Pollack, M., Renshaw, P. F., Kaufman, M. J., & Yurgelun-Todd, D. A. (2006). Methadone maintenance improves cognitive performance after two months of treatment. *Experimental and Clinical Psychopharmacology*, 14(2), 157-164.
- Grupp, K. (2006). Women one year following gender-specific treatment for alcohol and/or other drug dependency. *Journal of Addictions Nursing* 17, (1): 5-11.
- Guardianship Act 1995 (Tas) (Austl).*
- Gutheil, T.G. & Gabbard, G.O. (1998). Misuses and misunderstandings of boundary theory in clinical and regulatory settings. *American Journal of Psychiatry*, 155, 409-414.
- Hamilton, M. & Rumbold, G. (2004). *Addressing drug problems: The case for harm minimisation*. In M. Hamilton, T. King, and A. Ritter (Eds) (pp. 129-143), *Drug use in Australia* (2nd ed.). Victoria, Australia: Oxford University Press.
- Havard, A., Teesson, M., Darke, S. & Ross, J. (2006). Depression among heroin users: 12 month outcomes from the Australian Treatment Outcomes Study (ATOS). *Journal of Substance Abuse Treatment*, 30(4), 355-62.
- Haw, C., & Hawton, K. (2011). Problem drug use, drug misuse and deliberate self-harm: Trends and patient characteristics, with a focus on young people, Oxford, 1993-2006. *Social Psychiatry and Psychiatric Epidemiology*. 46(2) 85-93.
- Health Practitioners Regulation National Law (Tasmania) Act 2010 (Tas) (Austl).*
- Helfgott, S. (1997). *Counselling significant others* In: Helfgott, S (ed). *Helping Change: The Addiction Counsellors Training Program*. Perth: Western Australian Alcohol and Drug Authority.

- Henry-Edwards, S., Gowing, L., White, J., Ali, R., Bell, J., Brough, R., Lintzeris, N., Ritter, A., Quigley, A. (2003). *Clinical Guidelines and Procedures for the Use of Methadone in the Maintenance Treatment of Opioid Dependence*. National Drug Strategy, Canberra: Commonwealth of Australia.
- Hervé, S., Riachi, G., Noblet, C., Guillement, N., Tanasescu, S., Gorla, O., Thuillez, C., Tranvouez, J., Ducrotte, P. & Lerebours, E. (2004). Acute hepatitis due to buprenorphine administration. *European Journal of Gastroenterology & Hepatology*, 16(10), 1033-1037.
- Hser Y, Evans E, Huang D (2005). Treatment outcomes among men and women methamphetamine abusers in California. *Journal of Substance Abuse Treatment*, 28: 77-85.
- Jarvis, T.J., Copeland, J. & Walton L. (1998). Exploring the nature of the relationship between child sexual abuse and substance use among women. *Addiction*, 93, (6), 865-75.
- Kamina, A., Jaw, M., Butler, T., Levy, M., Corben, S., Kaldor, J. & Grant, L. (2007). Suicide risk among recently released prisoners in New South Wales, Australia. *Medical Journal of Australia*. 187(7), 387-90.
- Keene, J., Ahmed, S., Fenley, S., & Walker, M. (2004). A qualitative study of a successful shared care project for heroin use: the Berkshire Four Way Agreement. *International Journal of Drug Policy*, 15, 196.
- Kenny, P., Swan A., Berends, L., Jenner, L., Hunter, B., and Mugavin, J. (2009) *Alcohol and Other Drug Withdrawal: Practice Guidelines 2009*, Victoria: Turning Point Alcohol and Drug Centre.
- King, S. & Strain, J. (1990) Benzodiazepine use by chronic pain patients. *Clinical Journal of Pain*. Vol. 6(2), 143-7.
- Kinner, S. (2006). Continuity of health impairment and substance misuse among adult prisoners in Queensland, Australia. *International Journal of Prisoner Health*, 2(2), 101-13.
- Krinsky, C., Lathrop, S., Brown, P & Nolte, K. (2009). Drugs, detention and death: a study of the mortality of recently released prisoners. *American Journal of Forensic Medical Pathology*. 30(1) 6-9.
- Laslett, A., Dietze, P. & Dwyer, R., R. (2008). The oral health of street-recruited injecting drug users: Prevalence and correlates of problems. *Addiction*, 103(11), 1821-25.
- Lintzeris, N (2005, April) Induction into buprenorphine treatment. Presentation at Conference Safer options, Hamburg 19-21.
- Lintzeris, N. (2008). In Karch S. B. (Ed.), *Substitute prescribing: Buprenorphine maintenance prescribing*. Boca Raton, FL, US: CRC Press.

- Lintzeris, N., Clark, N., Muhleisen, P., Ritter, A. (2001). *National Clinical Guidelines and Procedures for the use of Buprenorphine in the Treatment of Heroin Dependence*. Canberra: Department of Health and Ageing.
- Lintzeris, N., Clark, N., Muhleisen, P., Ritter, A., Ali, R., Bell, J., Cowing, U., Hawkin, L., Henry-Edwards, S., Mattick, R., Monheit, B., Newton, U., Quigley, A., Whicker, S. & White, J. (2009). Chapter 12, *National clinical guidelines and procedures for the use of buprenorphine in the treatment of heroin dependence. Pharmacotherapies for the Treatment of Opioid Dependence*. USA: Informa Healthcare.
- Lintzeris, N., Clark, N., Winstock, A., Dunlop, A., Muhleisen, P., Gowing, L., Ali, R., Ritter, A., Bell, J., Quigley, A., Mattick, R., Monheit, B. & White, J. (2006). *National Clinical Guidelines and Procedures for the use of Buprenorphine in the Treatment of Opioid Dependence*. Canberra: National Drug Strategy.
- Lugo, R. A., Satterfield, K. L., & Kern, S. E. (2005). Pharmacokinetics of methadone. *Journal of Pain & Palliative Care Pharmacotherapy*, 19(4), 13-24.
- Maloney, E., Degenhardt, L., Darke, S., Mattick, R.P. & Nelson, E. (2007). Suicidal behaviour and associated risk factors among opioid-dependent individuals: A case-control study. *Addiction*, 102 (12), 1933-41.
- Marsh, A., & Dale, A. (2006). *Addiction Counselling: Content and Process*. Melbourne: IP Communications.
- Marsh, A., Dale, A. & Willis, L. (2007). *Evidence Based Practice Indicators for Alcohol and Other Drug Interventions: Summary (2nd ed.)*. Western Australian Drug and Alcohol Office: Perth: Western Australia.
- Marsh, A., Dale, A., & Willis, L. (2007). *A Counsellor's Guide to working with Alcohol and Drug Users (2nd ed.)*. Perth: Western Australian Government: Drug and Alcohol Office.
- Mattick, R., Breen, C., Kimber, J. & Davoli M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database of Systematic Reviews*. Issue 3. Art. No.: CD002209.
DOI:10.1002/14651858.CD002209.pub2
- Mattick, R., Digiusto, E., Doran, C., O'Brien, S., Shanahan, M., Kimber, J., Henderson, N., Breen, C., Shearer, J., Gates, J. & Shakeshaft, A. (2004). *National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD): Report of results and recommendations*. Canberra: Australian Government Department of Health and Ageing.
- Mattick, R., Digiusto, E., Doran, C., O'Brien, S., Shanahan, M., Kimber, J., Henderson, N., Breen, C., Shearer, J., Gates, J. & Shakeshaft, A. (2001). *National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD): Report of results and recommendations*. Sydney: National Drug and Alcohol Research Centre.

- McKeown, C. (2005). *The Summary Report: Prescribed Opioid Project 2005*, Public Health, Tasmania: Department of Health and Human Services.
- McLellan, A., Arndt, I., Metzger, D., Woody, G. & O'Brien, C. (1993). The effects of psychosocial services in substance abuse treatment. *Journal of the American Medical Association*. 269 (15), 1953-59.
- Mental Health Act 1996 (Tas) (Austl)*.
- Miller, N.S., Gold, M.S. & Pottash, A.C. (1989). A 12-step treatment approach for marijuana (cannabis) dependence. *Journal of Substance Abuse Treatment*, 16, 241-050.
- Mills, K., Deady, M., Proudfoot, H., Sannibale, C., Teeson, M., Mattick, R., & Burns, L. (2010). Guidelines on the management of co-occurring alcohol and other drug and mental health conditions in alcohol and other drug treatment settings. Sydney: National Drug and Alcohol Research Centre.
- Ministerial Council on Drug Strategy (2011). *The National Drug Strategy 2010-2015: A framework for action on alcohol, tobacco and other drugs*. Canberra: Department of Health and Ageing.
- Ministerial Council on Drug Strategy, (2004). *The National Drug Strategy: Australia's Integrated Framework 2004-2009*. Canberra: Commonwealth of Australia.
- Morin, C. M., & Wooten, V. (1996). Psychological and pharmacological approaches to treating insomnia: Critical issues in assessing their separate and combined effects. *Clinical Psychology Review*, 16(6), 521-542.
- Nathwani, N. & Gallagher, J. (2008). Methadone: Dental risks and preventive action. *Dental Update*, 35(8), 542-4, 547-8.
- National Pain Summit Initiative (2010). *National Pain Strategy* Retrieved June 16, 2011, from www.painsummit.org.au/strategy/Strategy-NPS.pdf/view.
- National Quality Measures Clearinghouse (2009). *Substance use disorders: percentage of patients aged 18 years and older with a diagnosis of current opioid addiction who were counselled regarding psychosocial and pharmacologic treatment options for opioid addiction with the 12 month reporting period*. Retrieved February 19, 2009, from http://www.qualitymeasures.ahrq.gov/summary/summary.aspx?doc_id=12989.
- Neale, J. (2004). Gender and Illicit Drug Use. *British Journal of Social Work*, 34, (6), 851-870.
- Neuman, M. G., Monteiro, M., & Rehm, J. (2006). Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. *Substance use & Misuse*, 41(10-12), 1395-1463.
- O'Brien, S. (2004) *Treatment Options for Heroin and Other Opioid Dependence: A Guide for Frontline Workers*. National Drug and Alcohol Research Centre: Sydney: University of New South Wales.

- O'Connor, P.G., Carroll, K.M., Shi, J.M., Schottenfeld, R.S., Kosten, T.R., & Rounsaville, B.J. (1997). Three methods of opioid detoxification in a primary care setting: A randomized trial. *Annals of Internal Medicine*, 127, 526 – 530.
- O'Neill, K., Baker, A., Cooke, M. & Collins, E. (1996). Evaluation of a cognitive-behavioural intervention for pregnant injecting drug users at risk of HIV infection. *Addiction*. 91(8), 1115-26.
- Ornstein, T., Iddon, J., Baldacchino, A., Sahakian, B., London, M., Everitt, B. & Robbins, T. (2000). Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. *Neuropsychopharmacology*, 23(2), 113-26.
- Personal Information Protection Act 2004(Tas) (Austl).*
- Petroulias, D., Brunn, A., Papadontas, M. & Roy, I. (2006). Clinical Treatment Guidelines for Alcohol and Drug Clinicians No13: Youth Alcohol and Drug Outreach. Victoria: Turning Point Alcohol and Drug Centre.
- Picozzi, A., Dworkin, S., Leeds, J. & Nash, J. (1972). Dental and associated attitudinal aspects of heroin addiction: A pilot study. *Journal of Dental Research*, 51(3), 869.
- Pinto, H., Rumball, D. & Holland R. (2008). Attitudes and knowledge of substance misusers regarding buprenorphine and methadone maintenance therapy. *Journal of Substance Use*. 13(3), 143-53.
- Poisons Act 1971 (Tas) (Austl).*
- Privacy Act (1988)*. Retrieved May 27, 2011, from <http://www.comlaw.gov.au/Series/C2004A03712>.
- Prosser, J., Cohen, L., Steinfeld, M., Eisenberg, D., London, E. & Galynker, I. (2006). Neuropsychological functioning in opiate dependent subjects receiving and following methadone maintenance treatment. *Drug and Alcohol Dependence*. 84(3), 240-47.
- Queensland Health (2008). *Queensland Opioid Treatment Program Clinical Guidelines*. Brisbane: Queensland Health.
- Queensland Health (203) Workplace Instructions; Alcohol Tobacco and Other Drug Service: Gold Coast: Gold Coast Health Services District.
- Rapeli, P., Fabritius, C., Kalska, H., & Alho, H. (2009). Memory function in opioid-dependent patients treated with methadone or buprenorphine along with benzodiazepine: Longitudinal change in comparison to healthy individuals. *Substance Abuse Treatment, Prevention, and Policy*, 4.
- Reid, G., Crofts, N., & Beyer, L. (2001). Drug treatment services for ethnic communities in Victoria, Australia: An examination of cultural and institutional barriers. *Ethnicity & Health*. 6(1), 13-26.

- Right to Information Act 2010* (Tas) (Austl).
- Riley, D., Sawka, E., Conley, P., Hewitt, D., Mitic, W., Poulin, C., Room, R., Single, E., & Topp, J. (1999). Harm reduction: Concepts and practices: A policy discussion paper. *Substance Use and Misuse*, 34(1) 9-24.
- Ritter, A. & Cameron, J. (2006). A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit drugs. *Drug and Alcohol Review*, 25, 611-624.
- Room, R (2004). Alcohol and harm reduction, then and now. *Critical Public Health*, 14(4), 329–344.
- Rowland, M.D, Henggeler, S.W., Gordon, A.M., Pickrel, S.G., Cunningham, P.B. & Edwards, J.E. (2000). Adapting multisystemic therapy to serve youth presenting with psychiatric emergencies: Two case studies. *Child Psychology and Psychiatric Review*, 5, 30-43.
- Sackett, D.L., Straus, S.E., Richardson, W.S., Rosenberg, W., & Haynes, R.B. (2000). *Evidence-based medicine: How to practice and teach EBM* (2nd ed.). New York: Churchill Livingstone.
- Sigma Methadone Syrup, Product Information,200. TGA Product and Consumer Medicine, 2003. Retrieved September 22, 2011, from <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=buprenorphine&r=/>
- Simojoki, K., Lillsunde, P., Lintzeris, N. & Alho H. (2010) Bioavailability of buprenorphine from crushed & whole buprenorphine (subutex) tablet. *European Addiction Research*. 16(2), 85-90.
- Simojoki, K., Lillsunde, P., Lintzeris, N., Alho, H. (2010). Bioavailability of buprenorphine from crushed and whole buprenorphine (Subutex) tablets. *European Addiction Research*, 16, 85-90.
- Simpson, D. D., Joe, G. W., & Bracy, S. A. (1982). Six-year follow-up of opioid addicts after admission to treatment. *Archives of General Psychiatry*, 39(11), 1318-1323.
- Simpson, D. D., Joe, G. W., Rowan-Szal, G. A., & Greener, J. M. (1997). Drug abuse treatment process components that improve retention. *Journal of Substance Abuse Treatment*, 14(6), 565-72.
- Simpson, D.D., & Sells, S.B. (1982). Effectiveness of treatment for drug abuse: An overview of the DARP research program. *Advances in alcohol and Substance Abuse*, 2, 7-29.
- Simpson, T. L. & Miller, W. R. (2002). Concomitance between childhood sexual and physical abuse and substance use problems. A review. *Clinical Psychology Review*, 22, 27–77.
- Smith, E. & Mistral, W. (2003). Shared care: lessons for one model of shared care nursing in primary care. *Drugs: education, prevention and policy*, 10, 263-270.

- Smith, S.M., Allwright, S., & O'Dowd, T. (2008). Does sharing care across the primary-specialty interface improve outcomes in chronic disease? A systematic review. *American Journal of Managed Care*, 14, 213-224.
- Sobell, L.C., Sobell, M.B., Leo, G. & Cancilla, A. (1988). Reliability of a timeline method: Assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. *British Journal of the Addictions*, 83(4), 393-402.
- Soyka, M., Lieb, M., Kagerer, S., Zingg, C., Koller, G., Lehnert, P., Limmer, C., Kuefner, H & Hennig-Fast, K. (2008). Cognitive Function During Methadone and Buprenorphine Treatment: Results of a randomized clinical trial. *Journal of Clinical Psychopharmacology*, 28(6), 699-703.
- Stafford, J. and Burns, L. (2011) *Australian Drug Trends 2010. Findings from the Illicit Drug Reporting System (IDRS)*. Australian Drug Trend Series No. 55. Sydney, National Drug and Alcohol Research Centre, University of New South Wales.
- Strang, J., McCambridge, J., Best, D., Beswick, T., Bearn, J., Rees, S. & Gossop, M. (2003). Loss of tolerance and overdose mortality after inpatient opiate detoxification: Follow up study: BMJ. *British Medical Journal*, 326 (7396), 959-60.
- Suboxone Sublingual Film, Product Information, *TGA Product and Consumer Medicine*, 2011. Retrieved September 22, 2011, from <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=buprenorphine&r=/>.
- Subutex, Product Information, *TGA Product and Consumer Medicine*, 2003. Retrieved September 22, 2011, from <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=methadone&r=/>.
- Swift, W., & Copeland, J. (1998) Treatment needs of women with alcohol and other drug problems: experiences and views of Australian treatment personnel. *Drug and Alcohol Review*, 17, 50-57.
- Teesson, M., Mills, K., Ross, J., Darke, S., Williamson, A. & Havard, A. (2008). The impact of treatment on 3 years' outcome for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). *Addiction* 103(1), 80-9.
- The Methadone Briefing, (1996). Retrieved September 14, 2011, from http://www.exchangesupplies.org/drug_information/briefings/the_methadone_briefing/methadone_briefing/section4.html#chemi
- The Royal Australasian College of Physicians, (2009). *Prescription Opioid Policy: Improving Management of Chronic Non-Malignant Pain and Prevention of Problems Associated with Prescription Opioid Use*. Sydney: Australasian Chapter of Addiction Medicine.

- The Royal Australasian College of Physicians, Australasian Chapter of Addiction Medicine (2006). *Clinical Guidelines: Assessing suitability for unsupervised medication doses in the treatment of opioid dependency*. Sydney: Australasian Chapter of Addiction Medicine.
- Thomas S (1997). Working with women. In Helfgott S (Ed.). *Helping change: The addiction counsellors training program*. Perth: Western Australian Government, Alcohol and Drug Office.
- United Nations Division for Social Policy and Development (2003). *Youth at the United Nations: FAQ*. Retrieved from <http://social.un.org>.
- van den Brink, W. & Hassen, C. (2006). Evidence-based treatment of opioid-dependent patients. *Canadian Journal of Psychiatry*, 51 (10) 635.
- Vazquez, V., Gury, C. & Laqueille, X. (2006). Methadone: from pharmacokinetic profile to clinical pharmacology. *Encephale* 32(4), 478-86.
- Vehicle and Traffic Act 1999* (Tas) (Austl).
- Vester & Buning (2005). *Buprenorphine: Critical Questions Examined*. Netherlands: Euro-Methwork.
- Vocci, F. (2008). Cognitive Remediation in the Treatment of Stimulant Abuse Disorders: A Research Agenda. *Experimental and Clinical Psychopharmacology*. 16(6) 484-97.
- Walsh, S.L, Preston, K.L., Bigelow, G.E. & Stitzer, M.L. (1995). Acute administration of buprenorphine in humans: partial agonist and blockade effects. *Journal of Pharmacology & Experimental Therapeutics*, 274(1) 361-372.
- Ward, J., Mattick, R. & Hall, W. (Eds). (1998). *Methadone Maintenance Treatment and other Opioid Replacement Therapies*. Amsterdam: Harwood Academic.
- Ward, J., Mattick, R.P. & Hall, W. (1998). How long is long enough? Answers to questions about the duration of methadone maintenance treatment. In J. Ward, R.P. Mattick & W. Hall. (Eds.), *Methadone Maintenance Treatment and Other Opioid Replacement Therapies*, Amsterdam: Harwood Academic Publishers, (pp. 305–336).
- Warren, J.I., Hurt, S., Lober, A.B., Bale, R., Friend, R., & Chauhan, P. (2002). Psychiatric symptoms, history of victimization, and violent behaviour among incarcerated female felons: An American perspective. *International Journal of Law and Psychiatry*, 25, 129-149.
- White, R., Beazley, P., Thompson, M., Charnaud, B., Cox, D., & Griffiths, V. (2007). Patients' views of treatment: Methadone vs. buprenorphine. *Journal of Substance use*, 12(5), 365-373.
- Winters, K. (1999). *Screening and Assessing Adolescents for Substance Use Disorders: Treatment Improvement Protocol (TIP) Series 31*. Rockville, MD: Substance Abuse and Mental Health Services.

World Health Organisation (2009). *Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence*. Geneva, WHO Press.

World Health Organization (1992). *International Classification of Diseases (10th ed.)* Geneva: World Health Organization.

Recommended Reading